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Abstract: Low dose aspirin (325 mg) is routinely used for primary and secondary prophylaxis 
of cardiovascular and cerebrovascular events. The use of low dose aspirin is associated with two- 
to four-fold greater risk of symptomatic or complicated peptic ulcers. Risk factors associated 
with low dose aspirin induced gastrointestinal toxicity includes prior history of ulcer or upper 
gastrointestinal (GI) bleeding, concomitant use of other nonsteroidal anti-inflammatory drugs, 
corticosteroid or warfarin, dual antiplatelet therapy, Helicobacter pylori (H. pylori) infection, 
and advanced age. Esomeprazole, like other proton pump inhibitors (PPIs) is very effective in 
decreasing the risk of aspirin induced gastrointestinal toxicity. Although evidence to support 
esomeprazole or other PPIs for primary prophylaxis in aspirin induced gastrointestinal toxicity 
is limited, its role in secondary prophylaxis is well established.
Keywords: esomeprazole, proton pump inhibitors, low dose aspirin, gastrointestinal toxicity, 
gastrointestinal bleeding
Low dose aspirin is routinely used for primary and secondary prophylaxis of car-
diovascular and cerebrovascular events.1,2 Low dose aspirin is commonly defined as 
325 mg daily as compared to dose 325 mg and up to 4 gm daily used for anti-
inflammatory and analgesic properties.3,4 It has been estimated that during the past 
two decades 50 million Americans have started taking aspirin for the prevention of 
heart attack and stroke.5
Like other nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin use can be 
limited by its association with mucosal injury to the upper GI tract, including the 
development of peptic ulcer disease (PUD) and complicating hemorrhage, perfora-
tion and death.6–8
Mechanism of antithrombotic action  
and GI toxicity
The primary effect of aspirin, like other NSAIDs, is to inhibit cyclooxygenase (COX) 
(prostaglandin synthase), thereby impairing the ultimate transformation of arachidonic 
acid to prostaglandins (PGs), prostacyclin, and thromboxanes.9 Two isoforms of the 
COX enzyme have been described: COX-1 and COX-2.
COX-1 (constitutional) is variably expressed in most tissues. It regulates normal 
cellular processes such as gastric cytoprotection and platelet aggregation. COX-2 
(inducible) is usually undetectable in most tissues; its expression is increased during 
states of inflammation.Therapeutics and Clinical Risk Management 2010:6 288
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Aspirin produces its antithrombotic effect by inhibiting 
the production of thromboxane A2 secondary to inhibition 
of COX-1.
The healthy gastric and duodenal mucosae constitu-
tively use COX-1 to produce its mucosal protective PGs. 
Some of the cytoprotective mechanisms of PGs include: 
stimulation of glycoprotein (mucin), bicarbonate, and phos-
pholipid secretion by cells, enhancement of mucosal blood 
flow and oxygen delivery to cells via local vasodilation, 
increased epithelial cell migration and enhanced epithelial 
cell proliferation.10 COX-1 inhibition by aspirin leading to 
prostaglandin depletion impairs these protective factors, 
resulting in a gastric environment that is more susceptible 
to topical attack by endogenous factors, such as acid, 
pepsin, and bile salts. The human stomach requires five to 
eight days to recover its COX-1 activity and its ability to 
synthesize protective PGs, suggesting a very slow turnover 
of gastric COX-1.11
Risk of GI toxicity with low  
dose aspirin
In a meta-analysis of 14 trials including over 57,000 patients, 
relative risk (RR) of major GI bleeding with the use of low 
dose aspirin as compared with placebo was 2.07 (95% con-
fidence interval (CI): 1.61–2.66). The absolute rate increase 
with aspirin above placebo was 0.12% per year.12 In another 
meta-analysis of 24 trials including low dose and high dose 
aspirin, the odds ratio (OR) for bleeding with aspirin was 
1.68% (95% CI: 1.51–1.88).5
It is interesting to note that patients using low dose 
aspirin are usually “high risk” cohorts for GI events. A large 
5-year observational cohort study showed 0.23% background 
incidence of upper GI bleeding hospitalization in the group 
matched to the low dose aspirin users – nearly four times the 
rate noted for the general population without medications 
or condition predisposing to bleeding – suggesting that 
the group taking low dose aspirin was a “higher risk” 
population.13
Risk factor for aspirin induced  
GI toxicity
In a large Danish cohort, factors that increased the risk of 
gastrointestinal bleeding included prior history of ulcers or 
gastrointestinal bleeding, corticosteroid use, anticoagulant 
therapy and addition of a nonaspirin nonsteroidal anti-
  inflammatory drug.13
Prior history of ulcer or upper GI 
bleeding
A case control study of patients hospitalized with upper 
GI bleeding identified a prior history of upper GI bleeding 
[OR: 6.5 (95% CI: 2.0–21.2)] and a prior history of ulcer 
[OR: 2.0 (95% CI: 1.0–4.1)] as significant risk factors for 
hospitalization with upper GI bleeding in patients taking 
low dose aspirin.14 An assessment of 903 patients discharged 
from a cardiology service on 75–325 mg of aspirin daily and 
followed for a mean of 45 months noted a significant asso-
ciation between hospitalization for upper GI bleeding and a 
history of peptic ulcer or upper GI bleeding (risk ratio: 3.1, 
95% CI: 1.5–6.5).15
Concomitant use of NSAID
Addition of nonaspirin NSAIDs to low dose aspirin increases 
the risk of upper GI bleeding by two- to fourfold.
A case control study for hospitalization for bleeding 
ulcer revealed that low dose aspirin alone was associated 
with an adjusted OR of 3.3 (2.5–4.4), while the combina-
tion of low dose aspirin plus an NSAID had an OR of 7.7 
(3.6–16.4).16
Annual incidence of hospital admission for upper GI 
bleeding was more than doubled when NSAIDs plus low 
dose aspirin were compared with low dose aspirin alone: 
1.4% vs 0.6%. The relative risk for aspirin alone was 2.6 
(2.2–2.9), and it was significantly higher: 5.6 (4.4–7) for low 
dose aspirin plus NSAID.13
Another similar study showed OR of 3.8 (1.8–7.8) for 
increased risk of upper GI bleeding with NSAID plus low 
dose aspirin compared to low dose aspirin alone.14
Helicobacter pylori infection
The interaction between H. pylori infection and NSAIDs 
in the pathogenesis of PUD remains controversial. A meta-
analysis, which included data from 25 observational studies, 
demonstrated that both H. pylori infection and nonselective 
NSAID use are independent risk factors, these risk factors are 
at least additive and possibly synergistic for the development 
of peptic ulcer and ulcer bleeding.17
Chan et al studied whether eradication of the H. pylori 
infection alone is effective in preventing recurrent bleeding. 
Two hundred and fifty patients taking aspirin who presented 
with upper gastrointestinal bleeding (which was confirmed 
by endoscopy) were then randomly assigned separately to 
receive 20 mg of omeprazole daily for six months or one week 
of eradication therapy followed by placebo for six months. Therapeutics and Clinical Risk Management 2010:6 289
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Prior to randomization, their ulcers were healed by daily treat-
ment with 20 mg of omeprazole for eight weeks or longer. The 
probability of recurrent bleeding during the six-month period 
was 1.9% for patients who received eradication therapy and 
0.9% for patients who received omeprazole (absolute differ-
ence, 1.0%; 95% CI: −1.9 to 3.9%).
This study showed that among patients with H. pylori 
infection and a history of upper gastrointestinal bleeding 
who are taking low dose aspirin, the eradication of H. pylori 
is equivalent to treatment with omeprazole in preventing 
recurrent bleeding.18
In another randomized trial, all aspirin users with 
H. pylori infection and a history of ulcer bleeding received 
a course of eradication therapy. They were then randomly 
assigned to receive lansoprazole (n = 62) or placebo 
(n = 61) for up to 12 months. It was found that 1.6% (95% 
CI: 0–9%) of patients in the lansoprazole group compared 
with 14.8% (95% CI: 7–26%) in the placebo group had 
recurrent ulcer bleeding. In the latter study, however, 
two-thirds of the patients with recurrent ulcer bleeding in 
the placebo group either had failure of H. pylori eradication 
or used concomitant NSAIDs, making data interpretation 
very difficult.19
In a prospective cohort study, the incidence rates of ulcer 
bleeding were compared among three different cohorts of 
low dose aspirin users, namely: patients without prior ulcer 
history who just started using aspirin (n = 548); aspirin users 
with prior ulcer bleeding and H. pylori infection who had 
successful eradication of H. pylori (n = 250); and H. pylori-
negative aspirin users who had prior ulcer bleeding (n = 118). 
All patients received low dose aspirin (160 mg daily) 
without a gastroprotective agent. After a median followup of 
48 months, the annualized incidence rate of ulcer bleeding 
in the three groups was 0.5%, 1.1%, and 4.6%, respectively. 
This study showed that confirmed eradication of H. pylori 
in aspirin users with prior ulcer bleeding significantly and 
substantially reduces the risk of recurrent bleeding.20
Two hundred and forty-five symptomatic elderly who 
were taking aspirin 75–300 mg daily, at least during the last 
3 months, were evaluated by endoscopy. One hundred and 
twelve patients were H. pylori-positive and 133 patients 
were H. pylori-negative. A significantly higher preva-
lence of peptic ulcers was observed in H. pylori-positive 
than in H. pylori-negative subjects (36.6% versus 15.8%, 
P = 0.0002). This study showed that H. pylori infection 
influences the prevalence of peptic ulcers and the cost effec-
tiveness of the PPI prevention therapy.21
Concomitant use of clopidogrel
Addition of clopidogrel to aspirin increases the risk of GI 
and non GI bleeding. In the ‘clopidogrel in unstable angina 
to prevent recurrent events’ (CURE) trial, major bleeding 
(GI and non GI causes of bleeding) was significantly more 
common in the clopidogrel plus aspirin group (3.7%) as 
compared with 2.7% in the aspirin plus placebo group; RR, 
1.38; 95% CI: 1.13 to 1.67; P = 0.001).22
In the ‘management of atherothrombosis with clopidogrel 
in high-risk patients with recent transient ischemic attacks 
or ischemic stroke’ (MATCH) trial, life threatening bleeding 
was higher in the group receiving aspirin and clopidogrel 
versus clopidogrel alone (96 [2.6%] vs 49 [1.3%]; absolute 
risk increase 1.3% [95% CI: 0.6 to 1.9]). The majority of 
bleeding was due to GI related complications.23
In the ‘clopidogrel for high atherothrombotic risk 
and ischemic stabilization, management, and avoidance’ 
(CHARISMA) trial, the rate of moderate bleeding was 2.1% 
in the clopidogrel plus aspirin group, as compared with 1.3% 
in the placebo plus aspirin group (RR, 1.62; 95% CI: 1.27 
to 2.08; P  0.001).24
These trials provide the evidence that combined low 
dose aspirin and clopidogrel therapy is associated with sig-
nificantly higher risk of GI bleeding when compared with 
low dose aspirin alone.
Age
Though data regarding high risk of GI complication with low 
dose aspirin use in older population is mixed,15,25 Patrono 
et al showed that the risk was below 0.5% for patients 
under 50 years old, while the risk was 4% in controls aged 
70–79 years old, and approximately 6% in controls over 
80 years old.26
Warfarin
In a comprehensive meta-analysis of 14 randomized con-
trolled trials (RCT) including 25,307 patients, results showed 
OR of 2.2 (95% CI: 1.64–2.96) for major extracranial bleed-
ing when aspirin alone was compared to combination of 
aspirin with warfarin.27
Corticosteroid
A cohort study showed that relative risk of hospitalization for 
upper GI bleeding was 5.3 (2.9–8.8) when low dose aspirin 
was used along with corticosteroid,28 as compared to RR 
of 2.6 (2.2–2.9) expected for the same population with low 
dose aspirin alone.13Therapeutics and Clinical Risk Management 2010:6 290
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Low versus high dose aspirin
Increasing the dose of aspirin above the cardioprotective 
dose increases the risk of GI bleeding compared to low 
dose aspirin.29 However, increasing the dose from 75–81 mg 
to 325 mg doesn’t increase the risk of GI bleeding. In 
a meta-analysis the relative risk of major GI bleeding 
with “lower” low dose aspirin (75–162.5 mg daily) was 
similar to the relative risk with “higher” low dose aspirin 
(162.5–325 mg daily): 2.22 (95% CI: 1.61–3.06) vs 2.35 
(95% CI: 0.98–5.66).12 Two other randomized controlled 
trials have reported similar findings.30,31
Enteric-coated aspirin has no significant protective effect 
on the clinically relevant end point of gastrointestinal bleed-
ing or other ulcer complications.32
Mucosal protection
Methods commonly employed to prevent the development 
of peptic ulceration and mucosal injury in patients taking 
aspirin include cotherapy with a PPI, high dose histamine-2 
receptor antagonists (H2RA), or the synthetic prostaglandin 
E1 analog, misoprostol.
Misoprostol
Limited number of studies address the role of misoprostol 
specifically in aspirin.33–36 Most of the studies have been in 
nonaspirin NSAIDs. A meta-analysis shows that cotherapy 
with misoprostol reduced the incidence of duodenal ulcers 
by 53% and gastric ulcer by 74% when compared with the 
placebo in patients with chronic NSAIDs use.37
The usefulness of misoprostol was limited by the occurrence 
of GI side effects, primarily cramping and diarrhea, and by com-
pliance problems related to four-times a day (q.i.d). dosage.
High dose H2RA
Systemic reviews have shown that double dose but not single 
dose H2RA are effective in reducing the risk of NSAID-
induced endoscopic gastric ulcers.37,38
Proton pump inhibitors
A number of studies have demonstrated that the PPIs are very 
effective for the healing and prevention of gastroduodenal 
ulcers associated with NSAIDs (including aspirin) when 
NSAIDs cannot be discontinued.18,19,39–43
Three trials specifically looked at the role of esomeprazole with 
low dose aspirin in prevention of gastroduodenal complications.
The role of aspirin with esomeprazole versus clopidogrel 
to prevent recurrent ulcer bleeding was assessed by Chan 
et al44 In a 12-month, prospective, randomized, double-blind 
trial that compared aspirin plus esomeprazole with clopi-
dogrel for patients who had previous aspirin-induced ulcer 
bleeding and were expected to continue low dose aspirin. 
Before randomization, healing of ulcers and eradication of 
H. pylori, if present, was documented. One hundred and fifty 
patients were assigned to receive aspirin plus esomeprazole 
and 161 patients were assigned to receive clopidogrel. The 
primary end point was recurrent ulcer bleeding as defined 
according to prespecified criteria – namely, hematemesis 
or melena with ulcers or bleeding erosions confirmed on 
endoscopy, or a decrease in the hemoglobin level of at least 2 
g per deciliter in the presence of endoscopically documented 
ulcers or bleeding erosions.
Recurrent ulcer bleeding occurred in 13 patients receiv-
ing clopidogrel and 1 receiving aspirin plus esomeprazole. 
The cumulative incidence of recurrent bleeding during the 
12 month period was 8.6% (95% CI: 4.1–13.1%) among 
patients who received clopidogrel and 0.7% (95% CI: 0–2.0%) 
among those who received aspirin plus esomeprazole (differ-
ence: 7.9% points; 95% CI: 3.4–12.4; P = 0.001).44
In a similar trial, the role of esomeprazole with aspirin 
versus clopidogrel for prevention of recurrent gastrointes-
tinal ulcer complications was assessed in a prospective, 
double-blind, randomized, controlled study of 170 patients. 
Patients who developed ulcer bleeding after the use of low 
dose and were expected to require continuous treatment 
with low dose aspirin were randomly assigned to treatment 
with esomeprazole 20 mg/day and aspirin 100 mg/day 
(n = 86) or clopidogrel 75 mg/day (n = 84) for 52 weeks. 
Before randomization, healing of ulcers and eradication of 
H. pylori, if present, was documented. The primary end point 
was recurrent ulcer complications. During a median follow up 
period of 52 weeks, no patient in the esomeprazole group, as 
compared with 9 patients in the clopidogrel group, developed 
recurrent ulcer complications. The cumulative incidences of 
recurrent ulcer complications were 0% in patients receiving 
esomeprazole and aspirin and 13.6% in patients receiving 
clopidogrel (absolute difference, 13.6%; 95% CI: 6.3–20.9; 
P = 0.0019).45
A multinational trial by Yeomans et al assessed the efficacy of 
esomeprazole 20 mg once daily vs the placebo for primary risk 
reduction of the gastroduodenal ulcers associated with continuous 
use of low dose aspirin. In this randomized, double-blind, placebo 
controlled study patients aged 60 years old, who were receiving 
aspirin 75–325 mg once daily and without baseline gastroduode-
nal ulcer at endoscopy, were randomized to esomeprazole 20 mg 
once daily or placebo for 26 wks. The presence of endoscopic Therapeutics and Clinical Risk Management 2010:6 291
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gastric and/or duodenal ulcers and esophageal lesions was 
assessed at weeks 8 and 26. Upper gastrointestinal symptoms 
were assessed at weeks 8, 16, and 26. The intention-to-treat 
population comprised 493 patients in the esomeprazole group 
and 498 patients in the placebo group. Twenty-seven patients 
(5.4%) in the placebo group developed a gastric or duodenal 
ulcer during 26 weeks’ treatment compared with eight patients 
(1.6%) in the esomeprazole group (life table estimates: 6.2% 
vs 1.8%; P = 0.0007). At 26 weeks, the cumulative proportion 
of patients with erosive esophagitis was significantly lower for 
esomeprazole versus the placebo (4.4% and 18.3%, respectively; 
P  0.0001). At 26 weeks, esomeprazole treated patients were 
more likely to experience resolution of heartburn, acid regurgita-
tion, and epigastric pain (P  0.05).3
Pharmacokinetics and pharmacodynamics of esomepra-
zole are described elsewhere,46 there is no pharmacokinetic 
interaction between esomeprazole (40 mg) and aspirin 
(325 mg) during repeated coadministration in healthy vol-
unteers.47
Discussion
The role of PPI in prevention of low dose aspirin-induced 
gastrointestinal toxicity should be considered in the context 
of whether PPI is being considered for primary or secondary 
prevention of gastrointestinal toxicity.
Though the role of PPI for prevention of peptic ulcer in 
patients with chronic low dose aspirin is well documented, 
the evidence to support their use for prevention of a first 
episode of aspirin induced GI bleeding is limited.
In many studies, the endoscopic visualization of an ulcer 
was utilized and interpreted as a surrogate end point for GI 
bleeding and other complications of gastric and duodenal 
ulcers. However, the end point that really matters in clinical 
practice and against which the clinically relevant therapeutic 
effect of PPI must ultimately be judged is the prevention 
of GI complications and upper GI bleeding in particular. 
More randomized trials with clinical rather than endoscopic 
endpoints are needed before primary prevention with a PPI 
can be widely recommended. One can consider eradication 
of H. pylori, if positive, in a high-risk population prior to 
PPI use.
The role of PPI for secondary prevention of peptic ulcer 
in patients with chronic low dose aspirin is proven beyond 
doubt; however it is not unreasonable to consider eradication 
of H. pylori alone without PPI prophylaxis in chronic low 
dose aspirin users.
It has been suggested that gastroprotective therapy with 
PPI should be used for patients considered to be at increased 
risk from chronic aspirin therapy. Increased risk was defined 
as a history of ulcer disease or complication, dual antiplatelet 
therapy, concomitant anticoagulant therapy, or more than one 
of the following risk factors: age 60 years, glucocorticoid 
use, or dyspepsia/gastroesophageal reflux disease (GERD).48 
Recent concerns about interaction between PPI and clopido-
grel is beyond the scope of this article, however it should be 
kept in mind when prescribing them together.49
In summary, further research is needed to determine the 
optimal regimen for primary prevention of GI toxicity among 
“high risk” low dose aspirin users. Based upon the currently 
available evidence, esomeprazole is very effective for sec-
ondary prevention of GI toxicity in low dose aspirin users.
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